Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Operating Leases (2021 - 2025)

Lyra Therapeutics has reported Operating Leases over the past 5 years, most recently at $25.4 million for Q4 2025.

  • Quarterly results put Operating Leases at $25.4 million for Q4 2025, down 15.92% from a year ago — trailing twelve months through Dec 2025 was $25.4 million (down 15.92% YoY), and the annual figure for FY2025 was $25.4 million, down 15.92%.
  • Operating Leases for Q4 2025 was $25.4 million at Lyra Therapeutics, down from $26.7 million in the prior quarter.
  • Over the last five years, Operating Leases for LYRA hit a ceiling of $33.4 million in Q1 2024 and a floor of $3000.0 in Q2 2022.
  • Median Operating Leases over the past 5 years was $4.9 million (2023), compared with a mean of $14.1 million.
  • Biggest five-year swings in Operating Leases: tumbled 99.68% in 2022 and later skyrocketed 162800.0% in 2023.
  • Lyra Therapeutics' Operating Leases stood at $379000.0 in 2021, then surged by 75.99% to $667000.0 in 2022, then surged by 3115.44% to $21.4 million in 2023, then soared by 41.09% to $30.3 million in 2024, then dropped by 15.92% to $25.4 million in 2025.
  • The last three reported values for Operating Leases were $25.4 million (Q4 2025), $26.7 million (Q3 2025), and $27.9 million (Q2 2025) per Business Quant data.